LPL Financial
GANX icon

LPL Financial’s Gain Therapeutics GANX Stock Holding History

LPL Financial’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$238K Buy
117,251
+13,000
+12% +$24K ﹤0.01% 5628
2026
Q1 		$202K Sell
104,251
-2,299
-2% -$5K ﹤0.01% 5489
2025
Q4 		$343K Buy
+106,550
New +$284K ﹤0.01% 5041

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

LPL Financial's GANX Position: Q2 2026 in Review

LPL Financial increased its Gain Therapeutics (GANX) stake by 12% in Q2 2026, buying an estimated $24K and bringing the position to 117,251 shares worth $238K. The position accounts for ﹤0.01% of the portfolio, ranked #5628.

LPL Financial first reported a position in GANX in Q4 2025 and has held it in 3 quarters since. The position peaked at $343K in Q4 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • LPL Financial held 117,251 shares of Gain Therapeutics worth $238K as of Q2 2026.
  • LPL Financial bought 13,000 Gain Therapeutics shares in Q2 2026, an estimated $24K.
  • Gain Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #5628 holding.
  • LPL Financial first reported a position in Gain Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • LPL Financial's Gain Therapeutics position peaked at $343K in Q4 2025.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.